Literature DB >> 17257635

Is there an inter-relationship between prostate specific antigen, kallikrein-2 and androgen receptor gene polymorphisms with risk of prostate cancer in north Indian population?

Rama D Mittal1, Dhruva K Mishra, K Thangaraj, Rajender Singh, Anil Mandhani.   

Abstract

Androgen receptor (AR) and kallikrein (KLK-2) regulates the PSA (prostate specific antigen) transcription and activation, respectively. We investigated the individual and combined risk of KLK-2, PSA and AR gene polymorphism in histologically confirmed CaP patients and healthy controls from north India. DNA was extracted from peripheral blood leucocytes pellet of 277 subjects. AR repeats analysis was done by PCR-Genscan method. PSA and KLK-2 were genotyped by PCR-RFLP method. Kruskal-Wallis test and logistic regression was applied for mean comparison and risk determination. A significant association for CaP risk was observed with short AR-CAG repeats (OR=3.36, p<0.001) and CC genotype of KLK-2 (OR=2.78, p=0.031), however, no association was found with PSA and AR-GGN repeat polymorphism. PSA/GG genotype was significantly associated with higher Gleason score (> or =7) of tumor (OR=6.23, p<0.01). No association was observed with other confounding variables such as PSA and age with any of these polymorphisms. Thus, we hypothesize that these polymorphisms may influence the etiology of CaP and may have the probability to become appropriate marker either independently or in combination. The combined information on serum PSA level, PSA (G/A), KLK-2 (C/T) genotypes and AR (CAG; GGN repeat) may assist in the deterrence of unnecessary biopsies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17257635     DOI: 10.1016/j.steroids.2006.12.004

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  7 in total

1.  The CAG repeat polymorphism of androgen receptor gene and prostate cancer: a meta-analysis.

Authors:  Mingliang Gu; Xiaoqun Dong; Xuezhi Zhang; Wenquan Niu
Journal:  Mol Biol Rep       Date:  2011-06-12       Impact factor: 2.316

2.  Involvement of different mechanisms for the association of CAG repeat length polymorphism in androgen receptor gene with prostate cancer.

Authors:  Xueying Mao; Jie Li; Xingxing Xu; Lara K Boyd; Weiyang He; Elzbieta Stankiewicz; Sakunthala C Kudahetti; Guangwen Cao; Daniel Berney; Guosheng Ren; Xin Gou; Hongwei Zhang; Yong-Jie Lu
Journal:  Am J Cancer Res       Date:  2014-11-19       Impact factor: 6.166

3.  Genetic variation in KLK2 and KLK3 is associated with concentrations of hK2 and PSA in serum and seminal plasma in young men.

Authors:  Charlotta Sävblom; Christer Halldén; Angel M Cronin; Torbjörn Säll; Caroline Savage; Emily A Vertosick; Robert J Klein; Aleksander Giwercman; Hans Lilja
Journal:  Clin Chem       Date:  2013-11-22       Impact factor: 8.327

4.  Association of Polymorphism rs198977 in Human Kallikrein-2 Gene (KLK2) with Susceptibility of Prostate Cancer: A Meta-Analysis.

Authors:  Lishan Wang
Journal:  PLoS One       Date:  2013-06-18       Impact factor: 3.240

5.  Expression of androgen receptor in breast cancer & its correlation with other steroid receptors & growth factors.

Authors:  Ashwani K Mishra; Usha Agrawal; Shivani Negi; Anju Bansal; R Mohil; Chintamani Chintamani; Amar Bhatnagar; Dinesh Bhatnagar; Sunita Saxena
Journal:  Indian J Med Res       Date:  2012-06       Impact factor: 2.375

Review 6.  Association between polymorphic CAG repeat lengths in the androgen receptor gene and susceptibility to prostate cancer: A systematic review and meta-analysis.

Authors:  Zhiqiang Qin; Xiao Li; Peng Han; Yuxiao Zheng; Hanyu Liu; Jingyuan Tang; Chengdi Yang; Jianzhong Zhang; Kunpeng Wang; Xiaokang Qi; Min Tang; Wei Wang; Wei Zhang
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

7.  Androgen receptor gene polymorphisms and risk of prostate cancer: a meta-analysis.

Authors:  Hong Weng; Sheng Li; Jing-Yu Huang; Zi-Qi He; Xiang-Yu Meng; Yue Cao; Cheng Fang; Xian-Tao Zeng
Journal:  Sci Rep       Date:  2017-01-16       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.